Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis

Survival of patients receiving systematic therapy for metachronous or synchronous metastatic renal cell carcinoma: a retrospective analysis

Abstract Background The differences in progression-free survival (PFS) and cancer-specific survival (CSS) of metastatic renal cell carcinoma (mRCC) patients according to treatment, type of metastasis, and Heng criteria risk are unclear. In this study, we compared survival according to various such p...

Full description

Bibliographic Details
Main Authors: Sung Han Kim, Dong-eun Lee, Boram Park, Jungnam Joo, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Format: Article
Language:English
Published: BMC 2019-07-01
Series:BMC Cancer
Subjects:
Renal cell carcinoma
Metastasis
Synchronous
Metachronous
Prognosis
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s12885-019-5900-1

Internet

http://link.springer.com/article/10.1186/s12885-019-5900-1

Similar Items